Free Trial
ASX:IBX

Imagion Biosystems (IBX) Stock Price, News & Analysis

Imagion Biosystems logo

About Imagion Biosystems Stock (ASX:IBX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
10.77 million shs
Average Volume
N/A
Market Capitalization
$3.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the MagSense nanoparticles for enhancing brain tumor imaging and diagnosis. The company was incorporated in 2016 and is based in San Diego, California.

Receive IBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imagion Biosystems and its competitors with MarketBeat's FREE daily newsletter.

IBX Stock News Headlines

Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Imagion Biosystems Announces New Securities Quotation
Imagion Biosystems Issues 7.5 Million Unquoted Securities
See More Headlines

IBX Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Imagion Biosystems investors own include EMCORE (EMKR), Allied Gaming & Entertainment (AGAE), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Academy Sports and Outdoors (ASO), Berkeley Energia (BKY) and Global X Cloud Computing ETF (CLOU).

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
Current Symbol
ASX:IBX
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-6,320,000.00
Net Margins
-265.26%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.92 million
Price / Cash Flow
3.00
Book Value
A($0.16) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$3.62 million
Optionable
Not Optionable
Beta
2.05
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (ASX:IBX) was last updated on 4/19/2025 by MarketBeat.com Staff
From Our Partners